Francois G. Gervais
Francois G. Gervais has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Nicole Sawyer
3 shared publicationsDanielle Denis
2 shared publicationsGary P. O’neill
2 shared publicationsA. Daniel Malebranche
1 shared publicationAdel Giaid
Montreal General Hospital, Montreal, Que., Canada H3G 1A4
1 shared publicationAnne Chateauneuf
11Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada H9R 4P8
1 shared publication
Latest Publications
- 1 January 2011
- Published by Elsevier in Molecular Pharmacology
- Vol. 79 (1) , 69-76
Pharmacological Characterization of MK-7246, a Potent and Selective CRTH2 (Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type 2 Cells) Antagonist
The chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells (CRTH2) is a G protein-coupled receptor that has been reported to modulate inflammatory responses in various rodent models of asthma, allergic rhinitis and atopic dermatitis. In this study, we describe the biological and pharmacological properties of {(7R)-7-[[(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}acetic acid (MK-7246), a novel synthetic CRTH2 antagonist. We show that MK-7246 1) has high affinity for the human, monkey, dog, rat, and mouse CRTH2, 2) interacts with CRTH2 in a reversible manner, 3) exhibits high selectivity over all prostanoid receptors as well as 157 other receptors and enzymes, 4) acts as a full antagonist on recombinant and endogenously expressed CRTH2, 5) demonstrates good oral bioavailability and metabolic stability in various animal species, 6) yields ex vivo blockade of CRTH2 on eosinophils in monkeys and sheep, and 7) significantly blocks antigen-induced late-phase bronchoconstriction and airway hyper-responsiveness in sheep. MK-7246 represents a potent and selective tool to further investigate the in vivo function of CRTH2.
- 1 January 2011
- Published by Elsevier in Molecular Pharmacology
- Vol. 79 (1) , 69-76
Pharmacological Characterization of MK-7246, a Potent and Selective CRTH2 (Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type 2 Cells) Antagonist
The chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells (CRTH2) is a G protein-coupled receptor that has been reported to modulate inflammatory responses in various rodent models of asthma, allergic rhinitis and atopic dermatitis. In this study, we describe the biological and pharmacological properties of {(7R)-7-[[(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}acetic acid (MK-7246), a novel synthetic CRTH2 antagonist. We show that MK-7246 1) has high affinity for the human, monkey, dog, rat, and mouse CRTH2, 2) interacts with CRTH2 in a reversible manner, 3) exhibits high selectivity over all prostanoid receptors as well as 157 other receptors and enzymes, 4) acts as a full antagonist on recombinant and endogenously expressed CRTH2, 5) demonstrates good oral bioavailability and metabolic stability in various animal species, 6) yields ex vivo blockade of CRTH2 on eosinophils in monkeys and sheep, and 7) significantly blocks antigen-induced late-phase bronchoconstriction and airway hyper-responsiveness in sheep. MK-7246 represents a potent and selective tool to further investigate the in vivo function of CRTH2.
- 1 June 2005
- Published by Elsevier in Molecular Pharmacology
- Vol. 67 (6) , 1834-1839
Identification of a Potent and Selective Synthetic Agonist at the CRTH2 Receptor
The chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells (CRTH2) is a G protein-coupled receptor whose function in vivo has been incompletely characterized. One of the reasons is that its current known ligands, prostaglandin D2 and some of its metabolites, have either poor selectivity for CRTH2 or are metabolically unstable in vivo. In this study, we describe the biological and pharmacological properties of L-888,607, the first synthetic potent and selective CRTH2 agonist. We show that L-888,607 exhibits 1) subnanomolar affinity for the human CRTH2 receptor, 2) high selectivity over all other prostanoid receptors and other receptors tested, 3) agonistic activity on recombinant and endogenously expressed CRTH2 receptor, and 4) relative stability in vivo. L-888,607 thus represents a suitable tool to investigate the in vivo function of CRTH2.
- 1 June 2005
- Published by Elsevier in Molecular Pharmacology
- Vol. 67 (6) , 1834-1839
Identification of a Potent and Selective Synthetic Agonist at the CRTH2 Receptor
The chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells (CRTH2) is a G protein-coupled receptor whose function in vivo has been incompletely characterized. One of the reasons is that its current known ligands, prostaglandin D2 and some of its metabolites, have either poor selectivity for CRTH2 or are metabolically unstable in vivo. In this study, we describe the biological and pharmacological properties of L-888,607, the first synthetic potent and selective CRTH2 agonist. We show that L-888,607 exhibits 1) subnanomolar affinity for the human CRTH2 receptor, 2) high selectivity over all other prostanoid receptors and other receptors tested, 3) agonistic activity on recombinant and endogenously expressed CRTH2 receptor, and 4) relative stability in vivo. L-888,607 thus represents a suitable tool to investigate the in vivo function of CRTH2.
- 1 January 2004
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 73 (1-2) , 87-101
Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa
- 1 January 2004
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 73 (1-2) , 87-101
Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa
- 1 December 2002
- Published by Wiley in British Journal of Pharmacology
- Vol. 137 (8) , 1163-1172
Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2
The recombinant human prostaglandin D2 (PGD2) receptor, hCRTH2, has been expressed in HEK293(EBNA) and characterized with respect to radioligand binding and signal transduction properties. High and low affinity binding sites for PGD2 were identified in the CRTH2 receptor population by saturation analysis with respective equilibrium dissociation constants (KD) of 2.5 and 109 nM. This revealed that the affinity of PGD2 for CRTH2 is eight times less than its affinity for the DP receptor. Equilibrium competition binding assays revealed that of the compounds tested, only PGD2 and several related metabolites bound with high affinity to CRTH2 (Ki values ranging from 2.4 to 34.0 nM) with the following rank order of potency: PGD2>13,14‐dihydro‐15‐keto PGD2>15‐deoxy‐Δ12,14‐PGJ2>PGJ2>Δ12‐PGJ2>15(S)‐15 methyl‐PGD2. This is in sharp contrast with the rank order of potency obtained at DP : PGD2>PGJ2>Δ12‐PGJ2>15‐deoxy‐Δ12,14‐PGJ2 >>>13,14‐dihydro‐15‐keto‐PGD2. Functional studies demonstrated that PGD2 activation of recombinant CRTH2 results in decrease of intracellular cAMP in a pertussis toxin‐sensitive manner. Therefore, we showed that CRTH2 can functionally couple to the G‐protein Gαi/o. PGD2 and related metabolites were tested and their rank order of potency followed the results of the membrane binding assay. By Northern blot analysis, we showed that, besides haemopoietic cells, CRTH2 is expressed in many other tissues such as brain, heart, thymus, spleen and various tissues of the digestive system. In addition, in situ hybridization studies revealed that CRTH2 mRNA is expressed in human eosinophils. Finally, radioligand binding studies demonstrated that two eosinophilic cell lines, butyric acid‐differentiated HL‐60 and AML 14.3D10, also endogenously express CRTH2. British Journal of Pharmacology (2002) 137, 1163–1172. doi:10.1038/sj.bjp.0704973
- 1 December 2002
- Published by Wiley in British Journal of Pharmacology
- Vol. 137 (8) , 1163-1172
Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2
The recombinant human prostaglandin D2 (PGD2) receptor, hCRTH2, has been expressed in HEK293(EBNA) and characterized with respect to radioligand binding and signal transduction properties. High and low affinity binding sites for PGD2 were identified in the CRTH2 receptor population by saturation analysis with respective equilibrium dissociation constants (KD) of 2.5 and 109 nM. This revealed that the affinity of PGD2 for CRTH2 is eight times less than its affinity for the DP receptor. Equilibrium competition binding assays revealed that of the compounds tested, only PGD2 and several related metabolites bound with high affinity to CRTH2 (Ki values ranging from 2.4 to 34.0 nM) with the following rank order of potency: PGD2>13,14‐dihydro‐15‐keto PGD2>15‐deoxy‐Δ12,14‐PGJ2>PGJ2>Δ12‐PGJ2>15(S)‐15 methyl‐PGD2. This is in sharp contrast with the rank order of potency obtained at DP : PGD2>PGJ2>Δ12‐PGJ2>15‐deoxy‐Δ12,14‐PGJ2 >>>13,14‐dihydro‐15‐keto‐PGD2. Functional studies demonstrated that PGD2 activation of recombinant CRTH2 results in decrease of intracellular cAMP in a pertussis toxin‐sensitive manner. Therefore, we showed that CRTH2 can functionally couple to the G‐protein Gαi/o. PGD2 and related metabolites were tested and their rank order of potency followed the results of the membrane binding assay. By Northern blot analysis, we showed that, besides haemopoietic cells, CRTH2 is expressed in many other tissues such as brain, heart, thymus, spleen and various tissues of the digestive system. In addition, in situ hybridization studies revealed that CRTH2 mRNA is expressed in human eosinophils. Finally, radioligand binding studies demonstrated that two eosinophilic cell lines, butyric acid‐differentiated HL‐60 and AML 14.3D10, also endogenously express CRTH2. British Journal of Pharmacology (2002) 137, 1163–1172. doi:10.1038/sj.bjp.0704973